ZA200703712B - Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha - Google Patents

Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha

Info

Publication number
ZA200703712B
ZA200703712B ZA200703712A ZA200703712A ZA200703712B ZA 200703712 B ZA200703712 B ZA 200703712B ZA 200703712 A ZA200703712 A ZA 200703712A ZA 200703712 A ZA200703712 A ZA 200703712A ZA 200703712 B ZA200703712 B ZA 200703712B
Authority
ZA
South Africa
Prior art keywords
inhibitors
alpha
necrosis factor
tumor necrosis
tricyclic compounds
Prior art date
Application number
ZA200703712A
Other languages
English (en)
Inventor
Bansi Lal
Usha Ghosh
Tulsidas More
Sunil Jadhav
Asha Kulkarni-Almeida
Radha Panicker
Ravindra Gupte
Somesh Sharma
Swati Bal-Tembe
Pravin Gagare
Shashikant Patil
Sapna Parikh
Anagh Damre
Original Assignee
Nicholas Piramal India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Piramal India Ltd filed Critical Nicholas Piramal India Ltd
Publication of ZA200703712B publication Critical patent/ZA200703712B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
ZA200703712A 2004-11-10 2007-05-08 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha ZA200703712B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1226MU2004 2004-11-10

Publications (1)

Publication Number Publication Date
ZA200703712B true ZA200703712B (en) 2010-04-28

Family

ID=38654748

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703712A ZA200703712B (en) 2004-11-10 2007-05-08 Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha

Country Status (15)

Country Link
US (3) US7834052B2 (de)
EP (1) EP1812419A2 (de)
JP (1) JP2008519824A (de)
KR (1) KR20070106981A (de)
CN (1) CN101076525B (de)
AR (1) AR056861A1 (de)
AU (1) AU2005303410B2 (de)
CA (1) CA2587671A1 (de)
IL (2) IL183038A0 (de)
MX (1) MX2007005470A (de)
NZ (1) NZ554937A (de)
RU (1) RU2406724C2 (de)
TW (1) TW200615273A (de)
WO (1) WO2006051477A2 (de)
ZA (1) ZA200703712B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2410841A4 (de) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc Substituierte bicyclische hcv-hemmer
EP2470013A4 (de) * 2009-08-27 2013-05-01 Us Health Verbindungen zur behandlung von malaria und zur verhinderung von malaria-übertragungen
WO2011075375A1 (en) * 2009-12-14 2011-06-23 Schering Corporation Fused tricyclic compounds for the treatment of inflammatory disorders
ES2441348T3 (es) * 2009-12-18 2014-02-04 Basilea Pharmaceutica Ag Antibióticos tricíclicos
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
CN106995382A (zh) * 2016-01-25 2017-08-01 济南和润化工科技有限公司 一种催化氢化法生产3-甲基-4-氨基苯甲酸的方法
US10793578B2 (en) * 2016-04-01 2020-10-06 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
US10669286B2 (en) * 2016-04-01 2020-06-02 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
EP3436460B1 (de) * 2016-04-01 2021-08-18 UCB Biopharma SRL Kondensierte pentacyclische imidazol-derivate als modulatoren der tnf-aktivität
WO2017167995A1 (en) * 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused hexacyclic imidazole derivatives as modulators of tnf activity
CN106831460A (zh) * 2017-02-24 2017-06-13 青铜峡市嘉华化工有限公司 3‑甲基‑4‑氨基苯甲酸的制备方法
USD817148S1 (en) * 2017-04-05 2018-05-08 Dormakaba Canada Inc. Locking system housing
CN107501106A (zh) * 2017-08-14 2017-12-22 中涛新材料有限公司 一种催化加氢制备3‑甲基‑4‑氨基苯甲酸的方法
EP3936192A4 (de) 2019-03-06 2022-11-16 Daiichi Sankyo Company, Limited Pyrrolopyrazolderivate
CN115010621B (zh) * 2022-07-21 2023-11-03 山东百启生物医药有限公司 一种4-溴-3-甲基苯甲腈的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48807A0 (en) * 1975-02-18 1976-03-31 Syntex Inc Novel 6,11-dihydrodibenzo-thiepin-11-ones,their preparation and compositions containing them
US4130654A (en) * 1978-01-30 1978-12-19 Syntex (U.S.A.) Inc. Novel 4-(8X-6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-yl)-4-oxobutyric acids, methods of preparation, compositions and uses thereof
IL57077A0 (en) * 1978-04-21 1979-07-25 Syntex Inc 6,11-dihydrodibenzo-thiepin-11-one s-oxides their preparation and pharmaceutical compositions containing them
GB2094790B (en) * 1981-03-13 1985-10-09 Spofa Vereinigte Pharma Werke Tricycle compounds
JPH0240662A (ja) 1988-08-01 1990-02-09 Ricoh Co Ltd 電子写真用感光体
US5036067A (en) * 1990-03-14 1991-07-30 Merck & Co., Inc. Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
JPH08119920A (ja) 1994-10-18 1996-05-14 Kyowa Hakko Kogyo Co Ltd 三環式アニリド誘導体
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
JPH11130772A (ja) 1997-10-28 1999-05-18 Kyowa Hakko Kogyo Co Ltd 含窒素複素環化合物
CO4980885A1 (es) 1997-12-29 2000-11-27 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto
TW200614995A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Tricyclic guanidine derivatives as sodium-proton exchange inhibitors

Also Published As

Publication number Publication date
TW200615273A (en) 2006-05-16
WO2006051477A2 (en) 2006-05-18
CA2587671A1 (en) 2006-05-18
CN101076525B (zh) 2011-07-27
US20100324026A1 (en) 2010-12-23
MX2007005470A (es) 2007-07-10
WO2006051477A3 (en) 2006-08-03
KR20070106981A (ko) 2007-11-06
AU2005303410B2 (en) 2011-12-15
CN101076525A (zh) 2007-11-21
US7834052B2 (en) 2010-11-16
US20100305094A1 (en) 2010-12-02
RU2007121682A (ru) 2008-12-20
US7964631B2 (en) 2011-06-21
AR056861A1 (es) 2007-10-31
EP1812419A2 (de) 2007-08-01
IL210036A0 (en) 2011-02-28
NZ554937A (en) 2011-01-28
RU2406724C2 (ru) 2010-12-20
JP2008519824A (ja) 2008-06-12
IL183038A0 (en) 2007-09-20
AU2005303410A1 (en) 2006-05-18
US8163730B2 (en) 2012-04-24
US20070299050A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
ZA200703712B (en) Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
EP1954290A4 (de) Als kinase-hemmer verwendbare trizyklische verbindungen
EP1720613A4 (de) Kondensierte tricyclische verbindungen als hemmer von 17-beta-hydroxysteroid-dehydrogenase 3
HK1128090A1 (en) Rnai-mediated inhibition of tumor necrosis factor
AP2006003763A0 (en) Macrocyclic compounds as inhibitors of viral replication
IL184303A0 (en) Amino-pyridines as inhibitors of ??-secretase
IL183188A0 (en) Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors
EP1725565A4 (de) Kondensierte heterotricyclische verbindungen als inhibitoren der 17b-hydroxysteroiddehydrogenase 3
EP1845970A4 (de) Hemmer von tumornekrose-faktoren
PL2385053T3 (pl) Związki pośrednie do wytwarzania skondensowanych bicyklicznych inhibitorów mTOR
PT1874770E (pt) Fenilacetamidas adequadas como inibidores da proteina cinase
ZA200705736B (en) Intravenous formulations of PDE-5 inhibitors
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
ZA200703008B (en) Substituted bicyclic imidazo-3-ylamine compounds
SI2384753T1 (sl) Hidantoinski derivati kot inhibitorji celične nekroze
EP1718611A4 (de) 3-3-disubstituierte-oxindole als inhibitoren der initiation der translation
EP1756092A4 (de) Neue inhibitoren von rho-kinasen
ZA200608798B (en) Macrocyclic compounds as inhibitors of viral replication
EP1778693A4 (de) Als kinaseinhibitoren nützliche verbindungen von trizyklischem heteroaryl
EP1987838A4 (de) Neue verbindung zur tumortherapie
IL187694A0 (en) Bicyclic 6-alkylidene-penems as class-d beta-lactamases inhibitors
EP1908459A4 (de) Zusammensetzung zur prävention von krebs
IL176824A0 (en) Tricyclic benzazepine derivatives as squalene synthase inhibitors used for the treatment of cardiovascular diseases
ZA200700751B (en) Azalndoles useful as inhibitors of protein kinases
HK1105634A1 (en) Heteroatoms-containing tricyclic compounds